Danaher(US:DHR) ZACKS·2026-01-28 16:55Core Insights - Danaher Corporation's (DHR) fourth-quarter 2025 adjusted earnings were $2.23 per share, exceeding the Zacks Consensus Estimate of $2.22, marking a 4% year-over-year increase [1] - The company reported net sales of $6.84 billion, surpassing the consensus estimate of $6.79 billion, with a year-over-year growth of 4.5% driven by strong performance across all segments [1] Financial Performance - DHR's core sales increased by 2.5% year over year in the quarter, with foreign-currency translations positively impacting sales by 2.5%, while acquisitions/divestitures had a negative impact of 0.5% [2] - For the full year 2025, DHR reported net revenues of $24.6 billion, a 3% increase year over year, and adjusted earnings of $7.80 per share, up 4.5% year over year [2] Segment Analysis - Life Sciences segment revenues reached $2.09 billion, up 2.5% year over year, exceeding the Zacks Consensus Estimate of $2.06 billion, with core sales increasing by 0.5% [3] - Diagnostics segment revenues totaled $2.72 billion, a 3% year-over-year increase, also surpassing the consensus estimate of $2.71 billion, with operating profit rising 14.3% year over year to $713 million [4] - Biotechnology segment revenues were $2.03 billion, up 9% year over year, exceeding the consensus estimate of $2.02 billion, with core sales increasing by 6% [5] Margin and Cost Structure - In Q4, Danaher's cost of sales increased by 8.5% year over year to $2.87 billion, while gross profit rose by 2% to $3.97 billion, resulting in a gross margin of 59.1%, slightly down from 59.5% in the previous year [6] - Operating profit increased by 5.4% year over year to $1.50 billion, although the operating margin declined to 19.1% from 20.4% in the year-ago quarter [7] Balance Sheet and Cash Flow - At the end of Q4, DHR had cash and equivalents of $4.62 billion, up from $2.08 billion at the end of 2024, while long-term debt increased to $18.4 billion from $15.5 billion [8] - The company generated net cash of $6.42 billion from operating activities in 2025, down from $6.69 billion in the previous year, with capital expenditures totaling $1.16 billion, a 17% decrease year over year [9] Future Outlook - For Q1 2026, Danaher expects low single-digit core sales growth year over year and anticipates adjusted earnings of $8.35-$8.50 per share [10][12] - The company projects a 3-6% increase in adjusted core sales for the full year 2026 [12]